Akademik Veri Yönetim Sistemi
EKRA 2024 3. ENDOKRİN KARDİYOVASKÜLER RENAL HASTALIKLAR VE ACİLLER KONGRESİ, Girne, Kıbrıs (Kktc), 30 Mayıs - 02 Haziran 2024, ss.22-23, (Özet Bildiri)
Background: Galectin-3 is involved in cardiac tissue inflammation as an inflammatory mediator. The development of cardiorenal syndrome (CRS) in heart failure (HF) patients is associated with a poor prognosis. This study aims to investigate rather serum galectin-3 levels can be used as a biomarker to predict the CRS in HF patients with reduced left ventricular ejection fraction (LVEF). Methods:
166 symptomatic HF patients (NYHA class II-III) with reduced LVEF (≤%40) were recruited prospectively between February 2018 and December 2019. CRS type 1 is defined an acute worsening of cardiac function leading to renal dysfunction. Patients were divided into two groups with and without CRS. Galectin-3 levels of all patients was determined. The primary outcome of this study was the occurrence of CRS. Results:
CRS developed in 41 patients. The galectin-3 levels were higher in CRS (+) patients compared to CRS (-) patients (20.7 ± 2.9 ng/mL vs. 17.8 ± 3.1 ng/mL, p < 0.001). After a multivariable analysis, galectin-3 level (OR:2.91, p = 0.003), NYHA class (OR:2.05, p = 0.006), creatinine (OR:3.00, p = 0.012), furosemide dose (OR:1.00, p = 0.045), ACEI /ARB use (OR:0.46, p = 0.022) were determined as the independent predictors of CRS development. The galectin-3 levels was shown to predict CRS development (AUC=0.761, p < 0.001).
Conclusıon:
Increasing serum Galectin-3 levels were associated with CRS development in patients with HF, suggesting that these levels can be useful prognostic biomarkers.